Scientists test powerful new Immune-Boosting cocktail against tough ovarian cancers
NCT ID NCT05231122
Summary
This study is testing whether adding a new immune-stimulating drug (CDX-1140) to two existing cancer drugs works better for women whose ovarian cancer has returned. About 80 participants will receive either the standard two-drug combination or the new three-drug combination, given through an IV every three weeks. The main goals are to see if the three-drug combo is safe and if it shrinks tumors more effectively, while also tracking survival and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.